Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Heymann

Showing results (21-30 of 243) with videos related to

Pageof 25
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 27, 2024
Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?Luis A Cordova, David González-Quintanilla, Dominique Heymann
Current Medicinal Chemistry|June 23, 2007
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumoursBenjamin Ory, Gatien Moriceau, Francoise Redini, et al.
In Vitro Cellular & Developmental Biology. Animal|June 16, 2007
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid bodyLaurence Duplomb, Maylis Dagouassat, Philippe Jourdon, et al.
Current Drug Discovery Technologies|August 12, 2008
RANKL/RANK/OPG: key therapeutic target in bone oncologyKosei Ando, Kanji Mori, Francoise Rédini, et al.
Future Oncology (London, England)|February 13, 2015
TRAIL-based therapy in pediatric bone tumors: how to overcome resistanceRomain Guiho, Kevin Biteau, Dominique Heymann, et al.
Drug Discovery Today|February 15, 2005
Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic toolsDominique Heymann, Yannick Fortun, Francoise Rédini, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 4, 2005
The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrowMostafa Romih, Joël Delécrin, Dominique Heymann, et al.
Expert Opinion on Investigational Drugs|September 17, 2016
Drugs in early clinical development for the treatment of osteosarcomaMarie-Françoise Heymann, Hannah K Brown, Dominique Heymann
Stem Cells (Dayton, Ohio)|November 11, 2006
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiationLaurence Duplomb, Maylis Dagouassat, Philippe Jourdon, et al.
Theranostics|August 2, 2019
Circulating Tumor Cells as a Tool for Assessing Tumor HeterogeneityMarta Tellez-Gabriel, Marie-Françoise Heymann, Dominique Heymann
Pageof 25

Showing results (21-30 of 243) with videos related to

Sort By:
Pageof 25
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 27, 2024
Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?Luis A Cordova, David González-Quintanilla, Dominique Heymann
Current Medicinal Chemistry|June 23, 2007
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumoursBenjamin Ory, Gatien Moriceau, Francoise Redini, et al.
In Vitro Cellular & Developmental Biology. Animal|June 16, 2007
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid bodyLaurence Duplomb, Maylis Dagouassat, Philippe Jourdon, et al.
Current Drug Discovery Technologies|August 12, 2008
RANKL/RANK/OPG: key therapeutic target in bone oncologyKosei Ando, Kanji Mori, Francoise Rédini, et al.
Future Oncology (London, England)|February 13, 2015
TRAIL-based therapy in pediatric bone tumors: how to overcome resistanceRomain Guiho, Kevin Biteau, Dominique Heymann, et al.
Drug Discovery Today|February 15, 2005
Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic toolsDominique Heymann, Yannick Fortun, Francoise Rédini, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 4, 2005
The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrowMostafa Romih, Joël Delécrin, Dominique Heymann, et al.
Expert Opinion on Investigational Drugs|September 17, 2016
Drugs in early clinical development for the treatment of osteosarcomaMarie-Françoise Heymann, Hannah K Brown, Dominique Heymann
Stem Cells (Dayton, Ohio)|November 11, 2006
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiationLaurence Duplomb, Maylis Dagouassat, Philippe Jourdon, et al.
Theranostics|August 2, 2019
Circulating Tumor Cells as a Tool for Assessing Tumor HeterogeneityMarta Tellez-Gabriel, Marie-Françoise Heymann, Dominique Heymann
Pageof 25